Shukra Pharmaceuticals Ltd

Shukra Pharmaceuticals Ltd has announced the closure of its trading window for dealing in the company's securities. This restriction applies to promoters, directors, key management personnel, insiders, and designated/connected persons, along with their immediate relatives. The window will remain closed from October 1, 2026, until 48 hours after the declaration of the Unaudited Financial Results for the quarter ended September 30, 2026. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and related circulars and the company's internal code. The date of the board meeting to approve these results will be announced separately.

Shukra Pharmaceuticals Limited has released its Annual Report for the fiscal year 2025-26. The report, digitally signed by Dakshesh Rameshchandra Shah, details the company's performance and operations over the past year. The registered office is located at Dev House, Ahmedabad, Gujarat. The filing indicates a standard annual reporting procedure, providing stakeholders with comprehensive information on the company's financial health and strategic direction.

Shukra Pharmaceuticals Ltd has issued a notice for its 33rd Annual General Meeting (AGM) to be held on September 28, 2026, at 12:00 P.M. IST via Video Conferencing. The agenda includes the adoption of audited financial statements for the fiscal year ended March 31, 2026, and the declaration of a final dividend of 1% (₹0.01 per equity share). Additionally, the meeting will address the re-appointment of Ms. Sanskruti Patel as an Executive Director and the regularization of Mr. Dinesh Chauhan's appointment as an Additional Independent Director.

Shukra Pharmaceuticals Ltd has announced the rescheduling of its 33rd Annual General Meeting (AGM) from September 22, 2026, to September 28, 2026. The AGM will now be held on Monday, September 28, 2026, at 12:00 p.m. IST via Video Conferencing (VC) / Other Audio-Visual Means (OAVM). Consequently, the book closure dates for the purpose of the AGM have been revised. The Register of Members and Share Transfer Books will remain closed from September 22, 2026, to September 28, 2026, inclusive. Remote e-voting periods will be adjusted accordingly. All other decisions from the August 22, 2026, board meeting, including the appointment of Mrs. Rupal Patel as Scrutinizer, remain unchanged.

Shukra Pharmaceuticals Ltd has announced Monday, September 21, 2026, as the record date for determining shareholder eligibility for a final dividend of ₹0.01 per equity share. This dividend is for the financial year ended March 31, 2026, and is subject to declaration by the company's members at the upcoming 33rd Annual General Meeting (AGM) scheduled for September 28, 2026. The payment of the dividend, if declared, will be made to shareholders recorded as of the specified record date, in compliance with SEBI LODR Regulations.

Shukra Pharmaceuticals Ltd announced the allotment of 11,73,000 fully paid-up equity shares of Re.1/- each to Navkar Surgical Gujarat Limited, a promoter, upon conversion of warrants. The conversion was made for cash, with the receipt of the remaining exercise price of Rs.26.67/- per share warrant, aggregating to Rs.3,12,83,910/-. This allotment increases the company's paid-up equity capital from Rs.43,96,14,440/- to Rs.44,07,87,440/-. Following this, 17,35,000 warrants remain outstanding for conversion.

Shukra Pharmaceuticals Ltd announced that its Board of Directors has approved a change in the company's name to Shukra Medtech Limited. This change is subject to shareholder and regulatory approvals. The company will also alter its Memorandum of Association to reflect the new name and main objects. The Board also approved the Director's Report and Secretarial Audit Report for the year ended March 31, 2026, and convened the 33rd Annual General Meeting (AGM) for September 25, 2026, to be held via Video Conferencing. The Register of Members and Share Transfer Books will be closed from September 19 to September 25, 2026.

Shukra Pharmaceuticals Ltd has announced its listing on the National Stock Exchange of India Limited (NSE) on August 14, 2026. This dual listing on both NSE and BSE marks a significant milestone in the company's capital market journey. The company's strategic direction emphasizes a strong focus on Medical Technology, Artificial Intelligence, healthcare innovation, and technology-enabled healthcare solutions for future growth and diversification. This media coverage clarifies that it pertains to the NSE listing and strategic vision, not new material transactions.

Shukra Pharmaceuticals Ltd has announced a Board of Directors meeting scheduled for August 22, 2026. The primary agenda items include considering and approving a change in the company's name and object clause, subject to shareholder approval. The board will also approve the draft notice for a postal ballot to seek member consent for these changes, appoint a scrutinizer for the postal ballot, and approve the draft Director's Report and Secretarial Audit Report for the fiscal year ended March 31, 2026. Additionally, the meeting will fix the date, time, and venue for the Annual General Meeting (AGM), decide on book closure dates, and appoint a scrutinizer for remote e-voting and the AGM. The trading window for designated employees will be closed from August 17 to August 24, 2026.

Shukra Pharmaceuticals Ltd has entered into a Term Sheet with Borns Medical Robotics Pte Ltd, Singapore, to establish a strategic joint venture named B&S Robotics Private Limited. This JV will focus on the design, manufacture, distribution, and servicing of AI-enabled surgical robotic systems in India and the Asia-Pacific region. Shukra will hold a 60% stake, contributing capital, its distribution network, and market capabilities, while Borns will contribute technology, IP, and manufacturing know-how for a 40% stake. The agreement outlines a framework for definitive agreements covering technology transfer, governance, and potential future demergers or listings. The JV aims to expand globally after obtaining necessary certifications.